February 16, 2019Open Access
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck Darmstadt, Germany; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Robert J. Motzer
Université Claude Bernard Lyon 1
K
Konstantin Penkov
City Clinical Hospital No 31
John B.A.G. Haanen
Leiden University
Journals
New England Journal of Medicine
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
Actions
Institutions
Brigham and Women's Hospital
Dana-Farber Cancer Institute
McGill University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...